Skip to main content
Top
Published in: Annals of Hematology 3/2018

01-03-2018 | Review Article

A comparison of TAFRO syndrome between Japanese and non-Japanese cases: a case report and literature review

Authors: Fabrice Coutier, Nadine Meaux Ruault, Thomas Crepin, Kevin Bouiller, Helder Gil, Sébastien Humbert, Isabelle Bedgedjian, Nadine Magy-Bertrand

Published in: Annals of Hematology | Issue 3/2018

Login to get access

Abstract

TAFRO syndrome was first described as a variant of multicentric Castleman’s disease with thrombocytopenia, anasarca, fever, renal dysfunction, and organomegaly. We report the case of a 25-year-old Caucasian male with diagnosis of TAFRO syndrome and present a literature review. The objective of the study was to compare TAFRO syndrome between Japanese and non-Japanese patients. Cases were included by searching the term “TAFRO” in the Medline database using PubMed between 2010 and 2016. The Student t test and Mann-Whitney U test were used to compare continuous variables. Fisher’s exact test was used for categorical variables. Statistical significance was set at p < 0.05. Forty-four cases were included. Thirty-two patients (73%) were of Japanese origin. Japanese patients were significantly older than non-Japanese ones (52.0 ± 13.6 years versus 36.9 ± 19.8 years, p = 0.0064) but there was no difference in gender. Creatinine level on admission was significantly higher in the non-Japanese group (1.87 ± 0.84 mg/dL versus 1.32 ± 0.57 mg/dL, p = 0.0347). There were no significant differences concerning lymphadenopathy, elevated number of megakaryocytes on bone marrow aspiration, autoimmune abnormalities, and the following parameters on admission: platelet count, hemoglobin, albumin, alkaline phosphatase (ALP). Corticotherapy was always used on induction for Japanese patients while it was only used in 75% of the cases on induction in non-Japanese patients (p = 0.0166). Our study was the first to compare TAFRO syndrome according to ethnicity. Japanese patients were significantly older and had a significantly lower creatinine level on admission than non-Japanese patients.
Literature
1.
go back to reference Castleman B, Towne VW (1954) Case records of the Massachussetts General Hospital: case no. 40231. N Engl J Med 250:1001–1005CrossRefPubMed Castleman B, Towne VW (1954) Case records of the Massachussetts General Hospital: case no. 40231. N Engl J Med 250:1001–1005CrossRefPubMed
2.
go back to reference Cronin ND, Warnke RA (2009) Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16:236–246CrossRefPubMed Cronin ND, Warnke RA (2009) Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16:236–246CrossRefPubMed
3.
go back to reference Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S et al (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53:57–61CrossRefPubMed Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S et al (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53:57–61CrossRefPubMed
4.
go back to reference Takai K, Nikkuni K, Shibuya H, Hashidate H (2010) Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites, and hepatomegaly. Rinsho Ketsueki 51:320–325PubMed Takai K, Nikkuni K, Shibuya H, Hashidate H (2010) Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites, and hepatomegaly. Rinsho Ketsueki 51:320–325PubMed
5.
go back to reference Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y (2013) Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporine A: a case report. J Clin Exp Hematop 53:95–99CrossRefPubMed Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y (2013) Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporine A: a case report. J Clin Exp Hematop 53:95–99CrossRefPubMed
6.
go back to reference Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H et al (2015) Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med 236:289–295CrossRefPubMed Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H et al (2015) Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med 236:289–295CrossRefPubMed
7.
go back to reference Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y et al (2016) Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103:686–692CrossRefPubMed Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y et al (2016) Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103:686–692CrossRefPubMed
8.
go back to reference Jouvray M, Terriou L, Meignin V, Bouchindhomme B, Jourdain M, Lambert M et al (2016) Pseudo-adult Still’s disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: an atypical presentation of multicentric Castleman’s disease. Discussion of TAFRO syndrome. Rev Med Int 37:53–57CrossRef Jouvray M, Terriou L, Meignin V, Bouchindhomme B, Jourdain M, Lambert M et al (2016) Pseudo-adult Still’s disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: an atypical presentation of multicentric Castleman’s disease. Discussion of TAFRO syndrome. Rev Med Int 37:53–57CrossRef
9.
go back to reference Kojima M, Nakamura N, Tsukamoto N, Otuski Y, Shimizu K, Itoh H et al (2008) Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol 16:391–398CrossRefPubMed Kojima M, Nakamura N, Tsukamoto N, Otuski Y, Shimizu K, Itoh H et al (2008) Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol 16:391–398CrossRefPubMed
10.
go back to reference Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T et al (2013) Japanese variant of multicentric Castleman’s disease associated with serositis and thrombocytopenia—a report of two cases: is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematol 53:79–85CrossRef Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T et al (2013) Japanese variant of multicentric Castleman’s disease associated with serositis and thrombocytopenia—a report of two cases: is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematol 53:79–85CrossRef
11.
go back to reference Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z et al (2015) Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis—TAFRO syndrome. Am J Hematol 90:1091–1092CrossRefPubMedPubMedCentral Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z et al (2015) Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis—TAFRO syndrome. Am J Hematol 90:1091–1092CrossRefPubMedPubMedCentral
12.
go back to reference Naifar M, Messedi M, Elleuch A, Snoussi M, Gouiaa N, Turki M et al (2016) TAFRO syndrome and monoclonal gammapathy: uncommon association! Curr Res Transl Med 64:43–47CrossRefPubMed Naifar M, Messedi M, Elleuch A, Snoussi M, Gouiaa N, Turki M et al (2016) TAFRO syndrome and monoclonal gammapathy: uncommon association! Curr Res Transl Med 64:43–47CrossRefPubMed
13.
go back to reference Simons M, Apor E, Butera JN, Treaba DO (2016) TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature. Case Rep Hematol 2016:4703608PubMedPubMedCentral Simons M, Apor E, Butera JN, Treaba DO (2016) TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature. Case Rep Hematol 2016:4703608PubMedPubMedCentral
14.
go back to reference Koduri PR, Parvez M, Kaza S, Pappu P, Anuradha S (2014) Castleman-Kojima disease in South Asian adolescent. J Clin Exp Hematop 54:163–166CrossRefPubMed Koduri PR, Parvez M, Kaza S, Pappu P, Anuradha S (2014) Castleman-Kojima disease in South Asian adolescent. J Clin Exp Hematop 54:163–166CrossRefPubMed
15.
go back to reference Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A et al (2012) Mixed-type multicentric Castleman’s disease developing during a 17-year follow-up of sarcoidosis. Intern Med 51:3061–3066CrossRefPubMed Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A et al (2012) Mixed-type multicentric Castleman’s disease developing during a 17-year follow-up of sarcoidosis. Intern Med 51:3061–3066CrossRefPubMed
16.
go back to reference Allegra A, Rotondo F, Russo S, Calabro L, Maisano V, Bacci F et al (2015) Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: a rare case report and review of the literature. Blood Cells Mol Dis 55:206–207CrossRefPubMed Allegra A, Rotondo F, Russo S, Calabro L, Maisano V, Bacci F et al (2015) Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: a rare case report and review of the literature. Blood Cells Mol Dis 55:206–207CrossRefPubMed
17.
go back to reference Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H et al (2013) Successful treatment of a patient with multicentric Castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52:1503–1507CrossRefPubMed Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H et al (2013) Successful treatment of a patient with multicentric Castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52:1503–1507CrossRefPubMed
18.
go back to reference Takasawa N, Sekiguchi Y, Takahashi T, Muryoi A, Satoh J, Sasaki T (2016) A case of TAFRO syndrome, a variant of multicentric Castleman’s disease, successfully treated with corticosteroid and cyclosporine A. Mod Rheumatol 14:1–5CrossRef Takasawa N, Sekiguchi Y, Takahashi T, Muryoi A, Satoh J, Sasaki T (2016) A case of TAFRO syndrome, a variant of multicentric Castleman’s disease, successfully treated with corticosteroid and cyclosporine A. Mod Rheumatol 14:1–5CrossRef
19.
go back to reference Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A et al (2015) Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy—a case report. Exp Hematol Oncol 4:3CrossRefPubMedPubMedCentral Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A et al (2015) Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy—a case report. Exp Hematol Oncol 4:3CrossRefPubMedPubMedCentral
20.
go back to reference Edahiro Y, Ichikawa K, Sunami Y, Koike M, Komatsu N (2015) Autoimmune hemolytic anemia in a patient with TAFRO syndrome. Rinsho Ketsueki 56:2346–2350PubMed Edahiro Y, Ichikawa K, Sunami Y, Koike M, Komatsu N (2015) Autoimmune hemolytic anemia in a patient with TAFRO syndrome. Rinsho Ketsueki 56:2346–2350PubMed
21.
go back to reference Ohya E, Mizutani M, Sakaguchi H, Sekine T (2016) Diffuse large B-cell lymphoma during corticosteroid therapy for TAFRO syndrome. Intern Med 55:2861–2867CrossRefPubMedPubMedCentral Ohya E, Mizutani M, Sakaguchi H, Sekine T (2016) Diffuse large B-cell lymphoma during corticosteroid therapy for TAFRO syndrome. Intern Med 55:2861–2867CrossRefPubMedPubMedCentral
22.
go back to reference Kawashima M, Usui T, Okada H, Mori I, Yamauchi M, Ikeda T et al (2015) TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol 20:1–5 Kawashima M, Usui T, Okada H, Mori I, Yamauchi M, Ikeda T et al (2015) TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol 20:1–5
23.
go back to reference Hiramatsu S, Ohmura K, Tsuji H, Kawabata H, Kitano T, Sogabe A et al (2016) Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi 39:64–71CrossRefPubMed Hiramatsu S, Ohmura K, Tsuji H, Kawabata H, Kitano T, Sogabe A et al (2016) Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi 39:64–71CrossRefPubMed
24.
go back to reference Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M et al (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226CrossRefPubMed Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M et al (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226CrossRefPubMed
25.
go back to reference Sakai K, Maeda T, Kuriyama A, Shimada N, Notohara K, Ueda Y (2016) TAFRO syndrome successfully treated with tocilizumab: a case report and systematic review. Mod Rheumatol 17:1–6CrossRef Sakai K, Maeda T, Kuriyama A, Shimada N, Notohara K, Ueda Y (2016) TAFRO syndrome successfully treated with tocilizumab: a case report and systematic review. Mod Rheumatol 17:1–6CrossRef
27.
go back to reference Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T et al (2014) The first report of adolescent TAFRO syndrome, a unique clinopathologic variant of multicentric Castleman’s disease. BMC Pediatr 14:139CrossRefPubMedPubMedCentral Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T et al (2014) The first report of adolescent TAFRO syndrome, a unique clinopathologic variant of multicentric Castleman’s disease. BMC Pediatr 14:139CrossRefPubMedPubMedCentral
28.
go back to reference Ferreira TS, Reis F, Appenzeller S (2016) Posterior reversible encephalopathy syndrome and association with systemic lupus erythematosus. Lupus 25:1369–1376CrossRefPubMed Ferreira TS, Reis F, Appenzeller S (2016) Posterior reversible encephalopathy syndrome and association with systemic lupus erythematosus. Lupus 25:1369–1376CrossRefPubMed
Metadata
Title
A comparison of TAFRO syndrome between Japanese and non-Japanese cases: a case report and literature review
Authors
Fabrice Coutier
Nadine Meaux Ruault
Thomas Crepin
Kevin Bouiller
Helder Gil
Sébastien Humbert
Isabelle Bedgedjian
Nadine Magy-Bertrand
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3138-z

Other articles of this Issue 3/2018

Annals of Hematology 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.